Increased Mortality In Rapamune Liver Transplant Study Sparks FDA Alert
This article was originally published in The Pink Sheet Daily
Wyeth notified the agency about increased mortality in the sirolimus arm of a comparative study and is seeking a safety update for the immunosuppressant’s labeling, the company said.
You may also be interested in...
FDA requires the labels for a handful of immunosuppressants used in kidney transplantation to reflect risk of infection, including activation of latent viral infections.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.